Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Nuvation Bio Inc.NYSE: NUVB
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $30.66M rose 12.1% year over year, behind the +18.2% change in trailing-twelve-month research & development. Sequentially, it fell 12.5% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.
Context
- Research & development amounted to 183.0% of revenue in FY2025, down 6475.1 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +12.1% toward the trailing-twelve-month pace of +18.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 115.11M USD
- Year-over-year change
- -78.0%
- 4-year CAGR
- +13.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 115.11M | -78.0% |
| FY2024 | 2024-12-31 | 524.19M | +635.3% |
| FY2023 | 2023-12-31 | 71.29M | -18.8% |
| FY2022 | 2022-12-31 | 87.82M | +27.2% |
| FY2021 | 2021-12-31 | 69.04M | — |
Research & Development vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 research & development of $128.85M is the 9th highest of the 11 companies compared; the peer median is $203.36M.
- Its year-over-year change of +18.2% is the 7th highest of 11, against a peer median of +39.2%.
- Research & development amounts to 75.8% of revenue for NUVB, versus a peer median of 456.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $324.68M | +6.6% | +49.8% | 456.5% | |
| LTM Jun 2026 | $294.44M | +79.9% | +83.9% | — | |
| LTM Sep 2026 | $283.32M | +31.2% | +43.9% | 252960.7% | |
| LTM Jun 2026 | $261.87M | +51.3% | +45.5% | — | |
| LTM Mar 2026 | $220.45M | +47.2% | +54.5% | 423.6% | |
| LTM Sep 2026 | $186.28M | +1.9% | +20.1% | 274.5% | |
| LTM Sep 2026 | $165.37M | +14.7% | +41.0% | — | |
| LTM Mar 2026 | $132.76M | -4.7% | -10.7% | 733.7% | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $127.65M | +60.8% | +33.1% | 590.6% | |
| LTM Jun 2026 | $39.85M | +63.8% | -10.3% | 12.8% | |
| Peer median (excluding NUVB) | $203.36M | +39.2% | +42.4% | 456.5% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.